PT3004090T - Compostos químicos - Google Patents
Compostos químicosInfo
- Publication number
- PT3004090T PT3004090T PT147270367T PT14727036T PT3004090T PT 3004090 T PT3004090 T PT 3004090T PT 147270367 T PT147270367 T PT 147270367T PT 14727036 T PT14727036 T PT 14727036T PT 3004090 T PT3004090 T PT 3004090T
- Authority
- PT
- Portugal
- Prior art keywords
- chemical compounds
- compounds
- chemical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827951P | 2013-05-28 | 2013-05-28 | |
| US201361915685P | 2013-12-13 | 2013-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3004090T true PT3004090T (pt) | 2017-12-22 |
Family
ID=50841880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147270367T PT3004090T (pt) | 2013-05-28 | 2014-05-27 | Compostos químicos |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US9155727B2 (pt) |
| EP (2) | EP3360875A1 (pt) |
| JP (1) | JP6286031B2 (pt) |
| KR (1) | KR20160013198A (pt) |
| CN (1) | CN105229004B (pt) |
| AP (1) | AP2015008858A0 (pt) |
| AU (1) | AU2014272856B2 (pt) |
| BR (1) | BR112015029455A8 (pt) |
| CA (1) | CA2911859A1 (pt) |
| CL (1) | CL2015003491A1 (pt) |
| CR (1) | CR20150629A (pt) |
| CY (1) | CY1120474T1 (pt) |
| DK (1) | DK3004090T3 (pt) |
| DO (1) | DOP2015000274A (pt) |
| ES (1) | ES2654161T3 (pt) |
| HK (1) | HK1222859A1 (pt) |
| HR (1) | HRP20171961T1 (pt) |
| HU (1) | HUE035738T2 (pt) |
| IL (1) | IL242559B (pt) |
| LT (1) | LT3004090T (pt) |
| ME (1) | ME02892B (pt) |
| MX (1) | MX361538B (pt) |
| NI (1) | NI201500167A (pt) |
| PE (1) | PE20160874A1 (pt) |
| PH (1) | PH12015502615A1 (pt) |
| PL (1) | PL3004090T3 (pt) |
| PT (1) | PT3004090T (pt) |
| RS (1) | RS56678B1 (pt) |
| RU (1) | RU2664109C2 (pt) |
| SG (1) | SG11201509393VA (pt) |
| SI (1) | SI3004090T1 (pt) |
| TN (1) | TN2015000516A1 (pt) |
| TW (1) | TWI653235B (pt) |
| UY (1) | UY35590A (pt) |
| WO (1) | WO2014191726A1 (pt) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
| TW201920090A (zh) | 2012-08-28 | 2019-06-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基－芳醯胺類及其做為治療ｂ型肝炎之醫藥劑的用途 |
| US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
| EP2981536B1 (en) | 2013-04-03 | 2017-06-14 | Janssen Sciences Ireland UC | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| PL2997019T3 (pl) | 2013-05-17 | 2019-03-29 | Janssen Sciences Ireland Uc | Pochodne sulfamoilotiofenamidu i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| ES2655518T3 (es) | 2013-10-23 | 2018-02-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| MX2016009449A (es) | 2014-02-05 | 2016-10-13 | Novira Therapeutics Inc | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). |
| SG11201606370YA (en) | 2014-02-06 | 2016-09-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| TW202323253A (zh) | 2014-12-18 | 2023-06-16 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| AU2016232801A1 (en) | 2015-03-19 | 2017-10-12 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
| CA2988620A1 (en) * | 2015-06-16 | 2016-12-22 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN108350062B (zh) | 2015-08-06 | 2022-10-14 | 达纳-法伯癌症研究所股份有限公司 | 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应 |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| RS62133B1 (sr) | 2015-10-01 | 2021-08-31 | Olema Pharmaceuticals Inc | Tetrahidro-1h-pirido[3,4-b]indol antiestrogeni lekovi |
| EP3378861B1 (en) * | 2015-11-12 | 2021-08-04 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| BR112018011607B1 (pt) | 2015-12-09 | 2024-01-30 | The Board Of Trustees Of The University Of Illinois | Composto, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, processo para preparação de um produto farmacêutico |
| EP3395809A4 (en) | 2015-12-22 | 2019-06-19 | Jiangsu Hengrui Medicine Co. Ltd. | BENZOPIPERIDIN DERIVATIVE, PRODUCTION METHOD AND MEDICAL USE THEREOF |
| CN109362222B (zh) | 2016-02-05 | 2021-03-19 | 益方生物科技(上海)股份有限公司 | 选择性雌激素受体降解物及其用途 |
| SG11201807708SA (en) * | 2016-04-01 | 2018-10-30 | Zeno Royalties & Milestones Llc | Estrogen receptor modulators |
| BR112018071048A2 (pt) | 2016-04-15 | 2019-05-07 | Janssen Sciences Ireland Uc | combinações e métodos que compreendem um inibidor da montagem de capsídeos |
| TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
| CA3022377A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
| WO2017197904A2 (zh) * | 2016-05-08 | 2017-11-23 | 上海诚妙医药科技有限公司 | 帕布昔利布的新晶型及其制备方法及其用途 |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017216280A1 (en) | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| JP7018026B2 (ja) * | 2016-06-16 | 2022-02-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
| CN109415361B (zh) * | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| CN109843888B (zh) | 2016-10-24 | 2022-03-01 | 阿斯利康(瑞典)有限公司 | 可用于治疗癌症的6，7，8，9-四氢-3H-吡唑并[4，3-f]异喹啉衍生物 |
| WO2018129387A1 (en) | 2017-01-06 | 2018-07-12 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| WO2018130123A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的五环类化合物及其应用 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| CN110214140B (zh) * | 2017-01-30 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 雌激素受体调节剂 |
| US11311609B2 (en) | 2017-02-08 | 2022-04-26 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
| WO2018233591A1 (zh) * | 2017-06-20 | 2018-12-27 | 江苏恒瑞医药股份有限公司 | 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法 |
| NZ759691A (en) | 2017-06-29 | 2023-05-26 | G1 Therapeutics Inc | Morphic forms of git38 and methods of manufacture thereof |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| EA038160B1 (ru) * | 2017-11-30 | 2021-07-15 | Астразенека Аб | Модуляторы рецептора эстрогена |
| CN109867659A (zh) * | 2017-12-04 | 2019-06-11 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物的制备方法 |
| US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| JP7348663B2 (ja) * | 2018-02-23 | 2023-09-21 | センター フォー インテリジェント リサーチ イン クリスタル エンジニアリング，エセ．エレ． | ユビキノールの共結晶及びそれらを含む組成物 |
| CR20200378A (es) | 2018-03-14 | 2021-01-08 | Janssen Sciences Ireland Unlimited Co | Régimen posológico del modulador del emsalblaje de la cápside |
| TW202016084A (zh) * | 2018-05-30 | 2020-05-01 | 大陸商迪哲（江蘇）醫藥有限公司 | 選擇性雌激素受體下調劑和其用途 |
| PE20211207A1 (es) | 2018-06-21 | 2021-07-05 | Hoffmann La Roche | Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1- (3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso |
| BR112020025591A2 (pt) | 2018-07-03 | 2021-03-23 | The Board Of Trustees Of The University Of Illinois | ativadores da resposta da proteína não dobrada |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
| AU2018454987A1 (en) | 2018-12-24 | 2021-07-15 | InventisBio Co., Ltd. | Novel salts of selective estrogen receptor degraders |
| WO2020169784A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| JP2022543832A (ja) | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
| KR20220103977A (ko) * | 2019-11-04 | 2022-07-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제의 염 및 형태 |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
| JP2023509944A (ja) | 2020-01-10 | 2023-03-10 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用 |
| US20230129598A1 (en) | 2020-03-06 | 2023-04-27 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| MX2023001572A (es) * | 2020-08-05 | 2023-05-08 | Aizant Drug Res Solutions Private Limited | Formas farmaceuticas sólidas de palbociclib. |
| US20240002950A1 (en) | 2020-11-23 | 2024-01-04 | Sanofi | Panel of ER Regulated Genes for Use in Monitoring Endocrine Therapy in Breast Cancer |
| WO2022140744A1 (en) | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
| IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
| AU2022269568A1 (en) | 2021-05-03 | 2023-11-16 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| IL309986A (en) * | 2021-07-08 | 2024-03-01 | Olema Pharmaceuticals Inc | Methods for treating diseases related to estrogen receptors |
| JP2024525643A (ja) | 2021-07-09 | 2024-07-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 三環式テトラヒドロイソキノリン系誘導体の塩の形態 |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JP2000509373A (ja) | 1996-04-19 | 2000-07-25 | ノボ ノルディスク アクティーゼルスカブ | ホスホチロシン認識ユニットを有する分子のモジュレーター |
| FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| CN1331862C (zh) | 1999-04-28 | 2007-08-15 | 萨诺费－阿文蒂斯德国有限公司 | 作为ppar受体配体的二芳基酸衍生物 |
| FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2402549A1 (en) * | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines |
| US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
| CA2473441A1 (en) | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
| ATE404200T1 (de) | 2002-04-22 | 2008-08-15 | Univ Johns Hopkins Med | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| ES2427166T3 (es) | 2003-06-23 | 2013-10-29 | Ono Pharmaceutical Co., Ltd. | Compuesto heterocíclico tricíclico novedoso |
| NZ545032A (en) * | 2003-07-28 | 2009-02-28 | Smithkline Beecham Corp | Cycloalkylidene compounds as modulators of estrogen receptor |
| DE10335725A1 (de) | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate |
| EP1706404A2 (en) * | 2004-01-23 | 2006-10-04 | Chiron Corporation | Tetrahydrocarboline compounds as anticancer agents |
| KR100808742B1 (ko) * | 2004-03-11 | 2008-02-29 | 액테리온 파마슈티칼 리미티드 | 테트라하이드로피리도인돌 유도체 |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| AU2005302409A1 (en) | 2004-10-28 | 2006-05-11 | The Institutes For Pharmaceutical Discovery Llc | Substituted carboxylic acids |
| JP2008520683A (ja) | 2004-11-18 | 2008-06-19 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | タンパク質チロシンホスファターゼ阻害剤としてのヘテロシクリルビフェニル誘導体 |
| JP2008530136A (ja) | 2005-02-14 | 2008-08-07 | ミイカナ セラピューティクス インコーポレイテッド | ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物 |
| US20100113502A1 (en) * | 2005-03-22 | 2010-05-06 | Astrazeneca Ab | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands |
| US20070032385A1 (en) | 2005-06-20 | 2007-02-08 | Dunetz Joshua R | Sustainable chemical processes |
| JP2009536659A (ja) | 2006-05-09 | 2009-10-15 | ヘマクエスト・ファーマシューティカルズ，インコーポレーテッド | 血液疾患の治療法 |
| MX2009001946A (es) | 2006-08-23 | 2009-03-05 | Kudos Pharm Ltd | Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor. |
| CA2662218A1 (en) | 2006-08-29 | 2008-03-06 | Reinnervate Limited | Retinoid compounds and their use |
| US20100249234A1 (en) | 2007-04-10 | 2010-09-30 | Uwm Research Foundation, Inc. | Methods of reducing virulence in bacteria |
| WO2008124838A1 (en) | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Compounds that inhibit human dna ligases and methods of treating cancer |
| CA2683444A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| US20100184758A1 (en) | 2007-07-19 | 2010-07-22 | Dobbelaar Peter H | Beta carboline derivatives as antidiabetic compounds |
| EP2320896A4 (en) * | 2008-07-03 | 2012-08-29 | Osteogenex Inc | VINPOCETINE AND EBURNAMONINE DERIVATIVES FOR THE PROMOTION OF BONE GROWTH |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| US20120202801A1 (en) | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| CA2999345A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| WO2012112961A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating hypertension |
| WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
-
2014
- 2014-05-27 CA CA2911859A patent/CA2911859A1/en not_active Abandoned
- 2014-05-27 PE PE2015002429A patent/PE20160874A1/es active IP Right Grant
- 2014-05-27 AP AP2015008858A patent/AP2015008858A0/xx unknown
- 2014-05-27 TN TN2015000516A patent/TN2015000516A1/en unknown
- 2014-05-27 ES ES14727036.7T patent/ES2654161T3/es active Active
- 2014-05-27 US US14/287,332 patent/US9155727B2/en not_active Expired - Fee Related
- 2014-05-27 ME MEP-2017-292A patent/ME02892B/me unknown
- 2014-05-27 PT PT147270367T patent/PT3004090T/pt unknown
- 2014-05-27 CN CN201480028785.1A patent/CN105229004B/zh not_active Expired - Fee Related
- 2014-05-27 JP JP2016516235A patent/JP6286031B2/ja not_active Expired - Fee Related
- 2014-05-27 AU AU2014272856A patent/AU2014272856B2/en not_active Ceased
- 2014-05-27 WO PCT/GB2014/051607 patent/WO2014191726A1/en active Application Filing
- 2014-05-27 RS RS20171304A patent/RS56678B1/sr unknown
- 2014-05-27 TW TW103118498A patent/TWI653235B/zh not_active IP Right Cessation
- 2014-05-27 EP EP17196495.0A patent/EP3360875A1/en not_active Withdrawn
- 2014-05-27 BR BR112015029455A patent/BR112015029455A8/pt not_active Application Discontinuation
- 2014-05-27 LT LTEP14727036.7T patent/LT3004090T/lt unknown
- 2014-05-27 PL PL14727036T patent/PL3004090T3/pl unknown
- 2014-05-27 KR KR1020157036820A patent/KR20160013198A/ko not_active Application Discontinuation
- 2014-05-27 SI SI201430531T patent/SI3004090T1/en unknown
- 2014-05-27 RU RU2015151502A patent/RU2664109C2/ru active
- 2014-05-27 HU HUE14727036A patent/HUE035738T2/en unknown
- 2014-05-27 UY UY0001035590A patent/UY35590A/es not_active Application Discontinuation
- 2014-05-27 MX MX2015016428A patent/MX361538B/es active IP Right Grant
- 2014-05-27 DK DK14727036.7T patent/DK3004090T3/en active
- 2014-05-27 EP EP14727036.7A patent/EP3004090B1/en active Active
- 2014-05-27 SG SG11201509393VA patent/SG11201509393VA/en unknown
-
2015
- 2015-08-31 US US14/840,342 patent/US9616050B2/en active Active
- 2015-11-11 DO DO2015000274A patent/DOP2015000274A/es unknown
- 2015-11-12 IL IL242559A patent/IL242559B/en not_active IP Right Cessation
- 2015-11-24 PH PH12015502615A patent/PH12015502615A1/en unknown
- 2015-11-27 CL CL2015003491A patent/CL2015003491A1/es unknown
- 2015-11-27 NI NI201500167A patent/NI201500167A/es unknown
- 2015-11-30 CR CR20150629A patent/CR20150629A/es unknown
-
2016
- 2016-09-22 HK HK16111116.8A patent/HK1222859A1/zh not_active IP Right Cessation
-
2017
- 2017-02-28 US US15/445,000 patent/US10130617B2/en not_active Expired - Fee Related
- 2017-12-18 HR HRP20171961TT patent/HRP20171961T1/hr unknown
-
2018
- 2018-01-03 CY CY20181100009T patent/CY1120474T1/el unknown
- 2018-10-12 US US16/158,527 patent/US20190038607A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222859A1 (zh) | 化合物 | |
| HRP20180839T1 (hr) | Kemijske vrste | |
| AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
| GB201304245D0 (en) | Chemical compounds | |
| GB201309085D0 (en) | Compounds | |
| GB201302927D0 (en) | Compounds | |
| GB201310542D0 (en) | Compounds | |
| HK1214592A1 (zh) | 化合物 | |
| GB201309508D0 (en) | Compounds | |
| AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| EP3010923A4 (en) | PYRROLOCHINAZOLINVERBINDUNGEN | |
| EP2948457A4 (en) | COMPOUNDS | |
| GB201306794D0 (en) | Compounds | |
| GB201322733D0 (en) | Chemical compounds | |
| GB201310460D0 (en) | Compounds | |
| GB201313885D0 (en) | Chemical Compounds | |
| GB201306881D0 (en) | Chemical compounds | |
| GB201310464D0 (en) | Compounds | |
| GB201310115D0 (en) | Compounds | |
| GB201310047D0 (en) | Compounds | |
| GB201309728D0 (en) | Compounds | |
| GB201309015D0 (en) | Compounds | |
| GB201308975D0 (en) | Compounds | |
| GB201308409D0 (en) | Compounds | |
| GB201307938D0 (en) | Compounds |